免疫检查点阻断通过扩增效应 CD8⁺ T 细胞克隆增强淋巴细胞清除性化疗诱导的抗肿瘤免疫
Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
追踪肿瘤特异性 CD8(+) T 细胞反应
英文原题：Tracking tumor-specific CD8(+) T cell responses.
查看英文原题
Tracking tumor-specific CD8(+) T cell responses.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
在一篇近期文章中，Puig-Saus等人通过计算预测并实验验证了黑色素瘤患者中的新抗原特异性T细胞反应。他们鉴定出一组有限的新抗原，可被多克隆CD8+ T细胞识别，这是抗PD-1应答者的独特特征，并工程化改造了表达新抗原特异性TCR的自体肿瘤反应性T细胞，为未来的细胞疗法提供了概念验证。
展开英文摘要原文
In a recent article, Puig-Saus et al. computationally predict and experimentally validate neoantigen-specific T cell responses in patients with melanoma. They identify a restricted set of neoantigens recognized by polyclonal CD8 + T cells as a unique feature of anti-PD-1 responders and engineer autologous tumor-responsive T cells expressing neoantigen-specific TCRs, providing proof-of-concept for future cellular therapies.
论文信息
- 作者
- Burke KP、Markson SC、Sharpe AH
- 第一作者单位
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.United States
- 通讯作者单位
- Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Evergrande Center for Immunological Diseases, Harvard Medical School, Boston, MA, USA; Brigham and Women's Hospital, Boston, MA, USA. Electronic address: Arlene_Sharpe@hms.harvard.edu.United States
- 文献类型
- 非美国政府资助研究 · 美国 NIH 资助研究
- 期刊
- Trends in immunology2023 May
- 原文标识
- PubMed 37031062 · DOI 10.1016/j.it.2023.03.012
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →